Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ARK Innovation ETF

Markforged Holding Corp

Pacific Biosciences of California

Personalis Inc

Teladoc

Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.

5 Top Stocks Cathie Wood Bought This Week

Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.

Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down

June quarter sales were $522 million, representing 26% growth if one backs out last year's sales bump from Covid-19 tests

Exact Sciences Stock Falls After Earnings. Here's What Wall Street Is Saying.

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Megan Jones - Senior Director, Investor Relations Kevin Conroy - Chairman & Chief Executive Officer Jeff Elliott - Chief Financial Officer & Chief Operating Officer Everett Cunningham - Chief Commercial Officer Conference Call Participants Derik De Bruin - Bank of America Brandon Couillard - Jefferies Brian Weinstein - William Blair Catherine Schulte - Baird Dan Brennan - Cowen Vijay Kumar - Evercore ISI Dan Arias - Stifel Patrick Donnelly - Citi Jack Meehan - Nephron Research Mark Massaro - BTIG Puneet Souda - SVB Securities Kyle Mikson - Canaccord Alex Nowak - Craig-Hallum Capital Group Operator Good day, and welcome to the Exact Sciences Second Quarter 2022 Earnings Call. Today's call is being recorded.

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2022 Results - Earnings Call Transcript

Second quarter highlights Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision Oncology revenue of $154 million, and COVID-19 testing revenue of $14 million Total second quarter revenue, excluding COVID-19 testing, increased 26 percent compared to the second quarter of 2021, including 34 percent increase in Screening revenue and 12 percent increase in Precision Oncology revenue Screening revenue growth driven by improved sales team productivity, Cologuard marketing partnership with Katie Couric, Cologuard rescreens, and Cologuard use in 45-49 age group MADISON, Wis. , Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $521.6 million for the second quarter ended June 30, 2022, compared to $434.8 million for the same period of 2021.

Exact Sciences Announces Second Quarter 2022 Results

ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulating tumor DNA (ctDNA) positivity and recurrence intervals MADISON, Wis. , Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with the West German Study Group (WSG), an international research institution that focuses on practice-changing clinical studies in breast cancer.

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

MADISON, Wis. , Aug. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences to participate in August investor conference

Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.

Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?

CRISPR Therapeutics

First Commonwealth Financial

Roku

Tesla

Zoom Video

As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. The post 6 Cathie Wood Stocks to Buy on the Dip appeared first on InvestorPlace.

6 Cathie Wood Stocks to Buy on the Dip

Guardant Health Inc

Let's look beyond short-term price targets analysts assign.

2 Cancer-Focused Stocks That Could Soar, According to Wall Street

MADISON, Wis. , July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, applauds the recently announced Centers for Medicare and Medicaid Services (CMS) Calendar Year 2023 Physician Fee Schedule proposal, which considers follow-up colonoscopy to an at-home test as a preventive service.

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

MADISON, Wis. , July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2022 financial results after the close of the U.S. financial markets on August 2, 2022.

Exact Sciences schedules second quarter 2022 earnings call

Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.

Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Exact Sciences (EXAS) Surges 6.9%: Is This an Indication of Further Gains?

Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs

Beam Therapeutics

Intellia Therapeutics

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

5 Health Care Stocks Cathie Wood Favors

Ionis Pharma

Kratos Defense & Security Solutions

UiPath

Trimble

Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation. The post 5 Cathie Wood Stocks to Buy in June appeared first on InvestorPlace.

5 Cathie Wood Stocks to Buy in June

MADISON, Wis. , May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in Chicago, Illinois.

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Why Is Exact Sciences (EXAS) Down 22.5% Since Last Earnings Report?

The current tight macro environment is conducive to consolidation in Biotech. Exact Sciences needs to turn cash flow positive to avoid liquidity problems.

Exact Sciences Won't Likely Escape Consolidation In The Industry

Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

Exact Sciences continues to record strong growth and is expected to report growth for the foreseeable future. Regardless of the steady revenue growth, the EXAS stock is under a lot of selling pressure as the overall market continues its downward trajectory.

Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation

Oncotype DX® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent RxPONDER study, recently published in The New England Journal of Medicine MADISON, Wis. , April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022 Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer guideline update.i The test is now recommended for use in postmenopausal patients with up to three positive axillary lymph nodes and is the only test recommended for use in premenopausal patients with node-negative disease.

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up

Exact Sciences Corp's (NASDAQ: EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%.

News for Exact Sciences Stock (EXAS)